Timeless Herbal Care (“Timeless”) A premier Jamaican-based medical cannabis company, is pleased to announce it has been selected by Mount Sinai Hospital (New York) to participate in a ground-breaking clinical trial dedicated to evaluating the therapeutic effects and potential of cannabinoids for the treatment of opioid use disorder. Led by renowned global researcher Dr. Yasmine Hurd, the trial is to develop a novel and safe, efficacious non-opioid and non-addictive, FDA approved, cannabidiol (“CBD”) based treatment to address the severe epidemic of opioid addiction through anti-anxiety intervention. In 2017, the Dept. of Health and Human Services declared the U.S. Opioid Use epidemic a public health emergency, with studies showing 2.1 million people had an opioid use disorder, while another 11.4 million people misused prescription opioids.
The clinical trial will be led by renowned principal researcher, Dr. Yasmin L. Hurd, PhD, the Ward-Coleman Chair of Translational Neuroscience at the Icahn School of Medicine at Mount Sinai, New YorkCity, and Director of the Center for Addictive Disorders for the Mount Sinai Behavioral Health System. This trial will be the largest U.S. and first international large-scale, multi-site clinical trial that will include up to 540 patients spanning the United States, Canada, Australia, Europe, and Jamaica.
Under the direction of Mt. Sinai, Timeless will serve as a co-sponsor of this clinical trial with MediPharm Labs, a leader in specialized, research-driven cannabis extraction and cannabinoid isolation. Timeless will provide its proprietary formulations, Intellectual Property, and industry know-how, while MediPharm Labs will be the exclusive manufacturer of a proprietary hemp-derived CBD capsule. Timeless and Medipharm Labs will have joint ownership in the Intellectual Property developed during the clinical trials.
Timeless will lead international commercialization efforts for any products resulting from positive outcomes of this historic study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.